BUTAZOLIDIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Butazolidin, and when can generic versions of Butazolidin launch?
Butazolidin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in BUTAZOLIDIN is phenylbutazone. There are nine drug master file entries for this compound. Additional details are available on the phenylbutazone profile page.
Summary for BUTAZOLIDIN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 118 |
Patent Applications: | 3,522 |
Formulation / Manufacturing: | see details |
DailyMed Link: | BUTAZOLIDIN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for BUTAZOLIDIN
US Patents and Regulatory Information for BUTAZOLIDIN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | BUTAZOLIDIN | phenylbutazone | CAPSULE;ORAL | 008319-009 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Novartis | BUTAZOLIDIN | phenylbutazone | TABLET;ORAL | 008319-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |